New Peptide MIA-602 Shows Promise Against Leukemia by Blocking Growth Hormone

Acute Myeloid Leukemia (AML) is an aggressive blood cancer characterized by rapid growth of abnormal myeloid cells in the bone marrow, often leading to poor prognosis despite intensive chemotherapy. Current treatments for AML are often associated with significant toxicity and resistance, highlighting an urgent need for novel, targeted therapies. Research has shown that Growth Hormone-Releasing Hormone (GHRH) and its receptors are often overexpressed in various cancers, including AML, promoting tumor cell proliferation and survival. This study addresses the knowledge gap by investigating the therapeutic potential of GHRH antagonism as a novel strategy for treating AML.

Treatment with MIA-602 significantly inhibited tumor growth and improved survival in the AML xenograft model. Tumor volume in the MIA-602 treated group was reduced by an impressive 62% compared to the vehicle control (p<0.001). This reduction was accompanied by a significant increase in median survival time, extending from 20 days in controls to 35 days in the treated group, representing a 75% increase (p<0.01). Histopathological analysis revealed a 2.5-fold increase in apoptotic cells and a 40% reduction in the proliferation marker Ki-67 within the tumors of MIA-602-treated mice. MIA-602 treatment led to a 62% reduction in tumor volume and extended median survival by 75% in AML xenograft models, demonstrating potent anti-leukemic activity. Furthermore, molecular analysis showed that MIA-602 effectively downregulated the expression of IGF-1 (Insulin-like Growth Factor 1) and inhibited the activation of the ERK1/2 signaling pathway, both known to be crucial for AML cell survival and proliferation.